Table 6 List of Risk Factors and multivariate model parameters

From: Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold

Risk Factors

Multivariate model confounders

Age

Age

Sex

Sex

Site of acquisition

Site of acquisition (healthcare-associated Vs nosocomial)

Solid cancer

Hematological malignancy

Solid cancer

Biliary disease

Hematological malignancy

Neurological disorder

Biliary disease

Diabetes mellitus

Neurological disorder

Hypertension

Diabetes mellitus

Alcohol use disorder

Hypertension

Chronic renal failure

Alcohol use disorder

End-stage renal disease

Chronic renal failure

Liver cirrhosis

End-stage renal disease

Solid organ transplantation

Liver cirrhosis

Haematopoietic stem cell transplantation

Solid organ transplantation

COPD or bronchiectasis

Haematopoietic stem cell transplantation

Rheumatological disease

COPD or bronchiectasis

Ischemic heart disease

Rheumatologic disease

Heart failure

Ischemic heart disease

Neutropenia

Heart failure

Recent surgery

McCabe score

Chemotherapy

Charlson index

Immunosuppressive therapy

Neutropenia

Sepsis grade

Recent surgery

Site of infection

Chemotherapy

Previous anti-MRSA therapy

Mucositis

Previous VAN use

Immunosuppressive therapy

VAN MIC by BMD

ICU care

Interaction: age × sex

Previous anti-MRSA therapy

 

Previous vancomycin exposure

 

Vancomycin MIC by BMD

  1. COPD chronic obstructive pulmonary disease.